GE: DaTscan, flutemetamol studies to be presented at SNMMI meeting

05/30/2013 | (free registration)

GE Healthcare said findings from three studies of its DaTscan tracer and imaging agent flutemetamol will be discussed at the SNMMI Annual Meeting. Two of the studies focused on DaTscan applications for Parkinsonian syndromes. The third study compares 18F-flutemetamol quantification results with histopathology findings.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC